CAMBRIDGE, Mass.--(BUSINESS WIRE)--Knome, a life sciences company that interprets genomes to identify the genetic factors that influence disease risk, cancer progression and drug response, today announced the release of kGAP 2.0™, the second version of the company’s genome interpretation engine. kGAP 2.0 underlies the genome interpretation and comparison services that Knome provides researchers who seek to make genomic discoveries.
